Document:

srne-ex106_713.htm

 

Exhibit 10.6

..

AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT

This Amendment No. 1 to Stock Purchase Agreement (this "Amendment') is dated as of March 7, 2016 by and between TNK Therapeutics, Inc., a Delaware corporation (the "Purchaser"), and Richard P. Junghans, M.D., Ph.D., as the Stockholders' Representative (the ''Representative").

RECITALS

WHEREAS, the Purchaser, the Representative, BDL Products, Inc., a  Delaware corporation (the "Company"), the former stockholders of the Company (the "Former Company Stockholders") and Sorrento Therapeutics, Inc., a Delaware corporation ("Sorrento"), are parties to that certain Stock Purchase Agreement, dated as of August 7, 2015 (the "Purchase Agreement'), pursuant to which the Former Company Stockholders sold, upon the terms and conditions set forth in the Purchase Agreement, all of the issued and outstanding shares of capital stock of the Company to the Purchaser;

WHEREAS, pursuant to Section 12.3 of the Purchase Agreement, the Purchase Agreement may not be amended, modified, altered or supplemented except by written agreement between the Purchaser and the Representative;

WHEREAS, the Purchase Agreement provides, among other things, that if the Purchaser does not issue, for the principal purpose of capital-raising resulting in gross proceeds (individually or in the aggregate) to the Purchaser of at least $50,000,000, shares of its common stock or shares of a previously unissued series of preferred stock (a "Financing"), prior to March 15, 2016, then Sorrento will be obligated to issue shares of its common stock to the Former Company Stockholders;

WHEREAS, as of the date hereof, the Purchaser does not believe that it will complete a Financing prior to March 15, 2016; and

WHEREAS, the Purchaser and the Representative desire to amend the  Purchase  Agreement to extend the period of time during which the Purchaser must complete a Financing before Sorrento will be obligated to issued shares of its common stock to the Former Company Stockholders, and to make certain other related conforming changes to the Purchase Agreement.

Now THEREFORE, in consideration of the mutual covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows:

ARTICLE 1 

AMENDMENTS

1.1 Amendment to Section 1.4(b) of the Purchase Agreement. The  reference  to "April 15, 2016" in Section l.4(b) of the Purchase Agreement is hereby replaced with "October 15, 2016".

 

 

1.2 Amendment to Section l .6(a) of the Purchase Agreement. The first sentence of Section l.6(a) of the Purchase Agreement is hereby amended and restated to read as follows:

"In the event that a Qualified Financing has occurred and the closing of the IPO has not occurred on or before September 15, 2016, as promptly as possible, and in no event later than September 30, 2016 (the "Repurchase Closing"), Sorrento shall purchase the Purchaser Stock Consideration from the Stockholders (the "Repurchase'l"

1.3 Amendment to Section 5.14 of the Purchase Agreement. The reference to "April 30, 2016" in Section 5.14 of the Purchase Agreement is hereby replaced with "October 30, 2016".

1.4 Amendment to Definition of "Qualified Financing" in Exhibit A to the Purchase Agreement. The reference to "March 15, 2016" in the definition of "Qualified Financing" included in EXHIBIT A of the Purchase Agreement is hereby replaced with "September 15, 2016".

ARTICLE 2 

GENERAL PROVISIONS

2.1 Definitions. Capitalized terms in this Amendment but not otherwise defined in this Amendment shall have the meanings set forth in the Purchase Agreement.

2.2 Continuing Effectiveness. Except as modified by this Amendment, the Purchase Agreement shall remain in full force and effect and no party by virtue of entering into this Amendment is waiving any rights it has under the Purchase Agreement, and once this Amendment is executed by the parties hereto, all references in the Purchase Agreement to "the Agreement" or "this Agreement," as applicable, shall refer to the Purchase Agreement as modified by this Amendment.

2.3 Successors and Assigns. The provisions of this Amendment shall apply to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the parties to this Amendment.

2.4 Governing Law. This Amendment shall be governed by and construed m accordance with the internal laws (and not the law of conflicts) of the State of California.

2.5 Counterparts. This Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same instrument, and shall become effective when counterparts have been signed by each of the parties to this Amendment and delivered to the other parties to this Amendment; it being understood that all parties to this Amendment need not sign the same counterparts.

 

[Signature Page Follows]

 

 

 

	
 
	
2
	
 

 

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

	
THE PURCHASER: 

TNK THERAPEUTICS, INC.

	
 
	
 

	
By:
	
/s/ Henry Ji, Ph.D.

	
Name:
	
Henry Ji, Ph.D.

	
Title:
	
Chief Executive Officer

 

	
	
THE REPRESENTATIVE:

	
 

	
/s/ RICHARD P. JUNGHANS, M.D., Ph.D.

	
RICHARD P. JUNGHANS, M.D., Ph.D.Exhibit 10.01

 

 

2017 DIRECTOR COMPENSATION POLICY

Effective as of January 1, 2017

 

PURPOSE:                                The Director Compensation Policy (“Policy”) establishes meeting fees that the Federal Home Loan Bank of New York (“FHLBNY”) will pay to the Board of Directors (collectively, the “Board”; each member individually or severally, the “Directors”) of the FHLBNY and also sets forth the types of Director expenses that may be reimbursed.  The activities referred to in this Policy are those as to which the Board believes Director attendance is necessary and appropriate and which may be compensated.  The Policy has been prepared in accordance with Section 7 of the Federal Home Loan Bank Act (“Bank Act”) and the regulations of the Federal Housing Finance Agency (“FHFA”) regarding Director compensation and expenses.

 

I.           2017 DIRECTOR FEES

 

A.        Board Chairman

 

The maximum fee opportunity for 2017 for the Chair of the Board shall be $120,000.

 

B.        Board Vice Chairman

 

The maximum fee opportunity for 2017 for the Vice Chair of the Board shall be $105,000.

 

C.        Committee Chairs

 

The maximum fee opportunity for 2017 for a Director serving as a Committee Chair shall be $105,000; however, such Director shall not receive any additional fee opportunity if he or she serves as Chair of more than one Committee.  The Board Chair and Board Vice Chair shall not receive any additional fee opportunity for serving as a Chair of one or more Board Committees.

 

D.        Other Directors

 

The maximum fee opportunity for 2017 for Directors other than the Chair, the Vice Chair, and the Committee Chairs shall be $95,000.

 

E.        Payments and Attendance

 

Each Director shall be paid an amount equal to approximately one-eighth of such Director’s maximum fee opportunity as described above for each Board meeting that is attended by said Director in 2017.  This formulation is based on nine scheduled Board meetings in 2017.  In addition, although attendance is expected at all Board meetings as per the FHLBNY’s Corporate Governance Guidelines, this formulation allows for one absence.  Such fees are to be paid on a quarterly basis in arrears.

 

FEDERAL HOME LOAN BANK OF NEW YORK · 101 PARK AVENUE · NEW YORK, NY 10178 · T: 212.681.6000 · WWW.FHLBNY.COM

 

 

Attendance at meetings by telephonic means shall be deemed acceptable for purposes of receiving compensation.

 

Directors may, in their sole discretion, elect to not receive meeting fees by notifying the Corporate Secretary.

 

F.        Payments and Performance

 

Payments to Directors may be reduced in the sole judgment of the Board Chair if the Chair determines such director’s Board performance to be significantly deficient.  The Board’s Corporate Governance and External Affairs Committee is authorized to, by a majority vote, make similar decisions pertaining to the performance of the Board Chair.

 

G.                 Fees Pertaining to Leadership Roles Relating to the Council of Home Loan Banks

 

In addition to the above compensation, a Director who serves as Chair of the Council of Federal Home Loan Banks or who serves as Chair of the Chair/Vice Chair Committee of the Council of Federal Home Loan Banks will receive a $10,000 stipend per year of service.  The stipend will be paid through quarterly payments of $2,500.

 

II.          2017 DIRECTOR EXPENSES

 

A.                        General Reimbursement Principles

 

1.                    Directors may be reimbursed for reasonable travel, subsistence and other related expenses incurred in connection with the performance of their official duties only as specified in the FHLBNY’s current policy covering the reimbursement of travel and other business-related items incurred by Directors.  However, under no circumstances shall Directors be reimbursed for gift or entertainment expenses.  (The principles in this Section II pertaining to permitted reimbursements shall also apply to those expenses paid for directly by the Bank to vendors and allocated to individuals in accordance with FHFA directives or guidance which may be issued from time to time.)

 

B.        Board and Board Committee Meetings

 

1.                    Reimbursement of reasonable expenses may be provided to Directors in connection with attendance at Board and Committee meetings as established herein.

 

C.        Stockholders’ Meetings

 

1.                    Reimbursement of reasonable expenses incurred by Directors attending FHLBNY stockholders’ meetings is permitted.

 

FEDERAL HOME LOAN BANK OF NEW YORK

 

2

 

D.        Industry Meetings

 

1.                    Reimbursement of Independent Directors’ expenses incurred while attending industry meetings or annual conventions of trade associations on a national level is permitted provided that a specific objective has been identified and that attendance has been specifically pre-approved by the Board of Directors.  Independent Directors attending industry events on behalf of the FHLBNY should register and identify themselves as Directors of the FHLBNY.

 

2.                    Reimbursement of Member Directors’ expenses incurred while in attendance at industry meetings or annual conventions of trade associations on a national level is not permissible, unless such attendance is incidental to a FHLBNY Board or Committee meeting.

 

E.        Meetings Called by the Federal Housing Finance Agency

 

1.                    Reimbursement of reasonable expenses may be provided to all Directors participating in any meetings called by the FHFA.

 

F.        Other Bank System Meetings

 

1.                    Reimbursement of reasonable expenses may be provided to all Directors who are invited to attend meetings of Federal Home Loan Bank System committees; Federal Home Loan Bank System director orientation meetings; and meetings of the Council of Federal Home Loan Banks and Council committees (e.g., the Chair/Vice Chair Committee).

 

G.        Expenses of Spouses/Guests

 

1.                    Expenses incurred by a Director’s spouse/guest while accompanying the Director to a meeting will not be reimbursed.

 

III.        PROCEDURES AND ADMINISTRATIVE MATTERS

 

A.                        Directors’ requests for reimbursement should be submitted to the Office of the Corporate Secretary within 90 days of incurring the reimbursable item(s).

 

B.                        Payment for and reimbursement of allowable business expenses of the Directors will require the approval of the Corporate Secretary or such officers designated by the Corporate Secretary.

 

C.                        Meetings of the Board and Committees thereof should usually be held within the district served by the FHLBNY.  Under no circumstances shall such meetings be held in any location that is not within the district without prior approval of the Board.  FHFA regulations prohibit any meetings of the Board of Directors (including committee, planning, or other business meetings) to be held outside the United States or its possessions and territories.

 

3

 

IV.        METHODOLOGY

 

In determining the appropriate and reasonable fee opportunities available to FHLBNY Directors for 2017 as described herein, the Board has taken into consideration the following factors:

 

·                              the desire to attract and retain highly qualified and skilled individuals in order to help guide a complex and highly-regulated financial institution that is subject to a variety of financial, reputational and other risks;

 

·                              the highly competitive environment for talent in the New York City metropolitan area — a center of world finance in which stock exchanges, securities companies and other sophisticated financial institutions are located;

 

·                              the demands of the Director position, including the time and effort that Directors must devote to FHLBNY and Board business — demands that have grown over the past several years;

 

·                              the overall performance of the FHLBNY, an institution that is a Federal Home Loan Bank System leader, a strong financial performer, a reliable source of liquidity for its customers, and a provider of a consistent dividend — and an institution which wishes to maintain this performance;

 

·                              information pertaining to compensation opportunities available to directors of other Federal Home Loan Banks; and

 

·                              director compensation surveys performed over time by outside compensation consulting firm McLagan, most recently in 2015 — surveys which have provided the Directors with the ability to compare Director compensation opportunities with compensation opportunities available at other institutions.

 

The Board will review the issue of appropriate and reasonable Director fee opportunities on an annual basis.

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]